| Autor: |
Arp AB; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Elfrink S; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., van Spriel AB; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. |
| Jazyk: |
angličtina |
| Zdroj: |
Critical reviews in oncogenesis [Crit Rev Oncog] 2020; Vol. 25 (3), pp. 251-273. |
| DOI: |
10.1615/CritRevOncog.2020036380 |
| Abstrakt: |
CD20-targeting antibodies are the current standard of care for patients with mature B-cell malignancies. However, many patients relapse or develop therapy resistance, which emphasizes the urgent need for new therapies. Here, we provide an overview of the biology of the CD20 protein and the mechanisms of action of CD20 antibodies currently used in the clinic. In addition, we discuss different mechanisms underlying therapy resistance, and recent advances made in the development of novel antibody-based therapeutics to improve clinical outcome of patients with mature B-cell malignancies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
